Vinay Parikh, PhD is an Associate Professor in the Cognition and Neuroscience area of the Department of Psychology at Temple University. Dr. Parikh also holds an affiliated faculty appointment in the Center for Substance Abuse Research at Lewis Katz School of Medicine. Previously, he served as the Director of Neuroscience Program in the College of Liberal Arts. Dr. Parikh’s research generally concerns neuromodulation of cognition in health and disease. For many years, his laboratory is engaged in delineating the contributions of cholinergic and glutamatergic signaling in modulation of distinct cognitive processes, specifically those involved in attention and executive functions. His research has also focused on the role of neurotrophins as key regulators of neurochemical circuit adaptations and cognitive functioning in aging and psychiatric disorders such as drug addiction and schizophrenia.
Recent areas of interest include genetic and cellular substrates of cognitive reserve and resilience in aging, and neurobehavioral biomarkers for Alzheimer’s disease. Dr. Parikh has authored/co-authored over 75 academic publications that include peer reviewed journal articles and book chapters, and has delivered more than 150 scientific presentations and invited talks at professional conferences and institutions. Dr. Parikh serves as an Associate Editor for Frontiers in Integrative Neuroscience, and as an editorial board member for European Journal of Neuroscience. He is an active reviewer of over 30 scholarly journals in the fields of Neuroscience, Psychology and Pharmacology. Dr. Parikh has also served on numerous grant review panels and scientific/education advisory committees.
Dr. Parikh earned Ph.D. in Life Sciences/Pharmacology from Punjabi University (India), following which he worked at Sun Pharmaceutical Industries Ltd. where he held the position of Group Leader in the New Drug Discovery Program. He relocated to the United States in 2001 and joined the Medical College of Georgia (Augusta, GA) as a postdoctoral fellow to obtain training in Neurochemistry/Neuropsychopharmacology. He integrated perspectives of Systems and Behavioral/Cognitive Neuroscience into his research by acquiring further postdoctoral training in Psychobiology and Neuroscience from the Ohio State University (Columbus, OH) and the University of Michigan (Ann Arbor, MI), respectively. He is a Temple faculty since 2009.
Cole RD, Zimmerman M, Kutlu MG, Matchanova A, Gould TJ, Parikh V. Cognitive rigidity and BDNF-mediated frontostriatal glutamate neuroadaptations during spontaneous nicotine withdrawal. Neuropsychopharmacology 2019; in press.
Duggan MR, Joshi S, Tan Y, Slifker M, Ross EA, Wimmer M, Parikh V. Transcriptomic changes in the prefrontal cortex of rats as a function of age and cognitive engagement. Neurobiology of Learning and Memory 2019; 163: 10735.
Zhou L, Fisher ML, Cole RD, Gould TJ, Parikh V, Ortinski PI, Turner JR. Neuregulin 3 signaling mediates nicotine-dependent synaptic plasticity in the orbitofrontal cortex and cognition. Neuropsychopharmacology 2018; 43: 1343-1354.
Yegla B, Parikh V. Developmental suppression of forebrain trkA receptors and attentional capacities in aging rats: A longitudinal study. Behavioral Brain Research 2017; 335: 111-121.
Koshy Cherian A, Kucinski A, Pitchers K, Yegla B, Parikh V, Kim Y, Valuskova P, Gurnan S, Blakely RD, Lindsley CW, Sarter M. Unresponsive choline transporter as a trait neuromarker and a causal mediator of bottom-up attentional biases. The Journal of Neuroscience 2017; 37: 2947-2959.
Koshy Cherian A, Parikh V, Wang Q, Wu Q, Mao-Draayer Y, Blakely RD, Sarter M. Hemicholinium-3 sensitive choline transport in human T lymphocytes: Evidence for use as a proxy for brain choline transporter (CHT) capacity. Neurochemistry International 2017; 108: 410-416.
Parikh V, Naughton SX, Yegla B, Guzman DM. Impact of partial dopamine depletion on cognitive flexibility in BDNF heterozygous mice. Psychopharmacology 2016; 233: 1361-1375.
Parikh V, Kutlu M, Gould TJ. nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: current trends and perspectives. Schizophrenia Research 2016; 171: 1-15.
Yegla B, Parikh V. Rejuvenating procholinergic treatments for cognition enhancement in AD: current challenges and future prospects. Frontiers in Systems Neuroscience 2015; 8: 254.
Yegla B, Parikh V. Effects of sustained proNGF blockade on attentional capacities in aged rats with compromised cholinergic system. Neuroscience 2014; 261:118-132.
D’Amore DE, Tracy BA, Parikh V. Exogenous BDNF facilitates strategy shifting by modulating glutamate dynamics in the dorsal striatum. Neuropharmacology 2013; 75: 312-323.
Parikh V, Ji J, Decker MW, Sarter M. Prefrontal β2 subunit-containing and α7 nAChRs differentially control glutamatergic and cholinergic signaling. The Journal of Neuroscience 2010; 30: 3518-3530.
Parikh V, Kozak R, Martinez V, Sarter M. Prefrontal acetylcholine release controls cue detection on multiple time scales. Neuron 2007; 56: 141-54.
Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML, Waller JL, Terry AV. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers and memory performance in aged rats. Journal of Pharmacology and Experimental Therapeutics 2006; 316:679-694.
Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nature Reviews Neuroscience 2005; 6:48-56.
Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor levels in never-medicated first-episode psychotic patients and medicated chronic schizophrenic patients. Schizophrenia Research 2003; 60:117-123.
NSCI 2122: Cellular Neuroscience
PSY 3566: Neurobiology of Learning and Memory
NSCI 5002: Neurochemistry
PSY 3561: Psychopharmacology
PSY 8310: Topical Seminar in Cognitive Psychology
NSCI 3087: Techniques in Neuroscience
NSCI 4197: Writing-intensive Capstone in Neuroscience